



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

26 April 2016
EMA/298458/2016 corr
Procedure Management & Committees Support Division
Scientific Committee Support Department

Scientific recommendation on classification of advanced therapy medicinal products

Article 17 – Regulation (EC) No 1394/2007

Disclaimer: This document is a summary for public release of a scientific recommendation on classification of advanced therapy medicinal products. The original text adopted by the Committee for Advanced Therapies (CAT) has been redacted to delete commercially confidential information.

The present scientific recommendation refers exclusively to the case as presented to the European Medicines Agency (EMA) without prejudice to future evaluations by the Agency

Brief description (or name where available) of the active substance(s)

Human autologous stromal vascular fraction (SVF) cells and human autologous adipose-derived mesenchymal stem cells (ADSC) cells

Brief description of the finished product

Stromal vascular fraction of adipose tissue and adipose-derived mesenchymal stem cells expanded in vitro, administrated in saline solution.

Proposed indication

Treatment of keloid scars

EMA/CAT conclusion

The committee adopted on 23rd March 2016 the following scientific recommendation.

On the basis that the product:

- is intended to treat a disease in humans;



- consists of engineered cells that have been subject to substantial manipulation, so that biological characteristics, physiological functions or structural properties relevant for the intended regeneration, repair or replacement are achieved;
- is administered to human beings with a view to regenerating, repairing or replacing a human tissue.

the EMA/CAT considers that the product falls within the definition of a tissue-engineered product.